IL6R and myocardial infarction: Although tocilizumab that blocks the IL-6 receptor (IL-6R) causes increased levels of triglycerides and therefore may not be suitable for treating chronic CVD, studies on the short-term administration of the IL-6R antagonist during acute MI have yielded encouraging results.